Director, Enterprise Cell and Gene Therapy, Labcorp
Speakers
-
Yoav Peretz, PhD
Global Scientific Director, Flow Cytometry and Targeted Cell Isolation, LabcorpBIOGRAPHY -
Vijay Ramakrishnan, PhD
Associate Director for Oncology Biomarkers, Biomarker Solution Center, LabcorpBIOGRAPHY -
Matthew Evans, PhD
Global Scientific Director, Genomics, LabcorpBIOGRAPHY -
Sarabjot (Sabi) Pabla, PhD
Head of Clinical and Research Bioinformatics, LabcorpBIOGRAPHY
Abstract
Watch the second of a three-part roundtable series that focus on approaches to accelerating your advanced therapy program by leveraging the combination of innovative technology and deep cross-industry insights from our cell and gene therapy scientists and operational leaders.
In this roundtable, the panel highlight the adoption of biomarker strategies that can create efficiency in your clinical cell therapy development efforts. Specific areas of focus include:
- Applying a precision medicine biomarker-driven strategy that takes into account specified context of use and its evolution as your development progresses
- Flow cytometry applications for the development of adoptive cell therapies (ACTs)
- Analytical tools to assess CRS, neurotoxicity and unintended/intended events for deployment and long-term follow-up of ACTs
- Comprehensive immune profiling applications including NGS, TCR β repertoire, and HLA haplotype to support translational research studies
Watch roundtable 1: Key Considerations for Driving Gene Therapy Programs Successfully Through IND/CTA and Beyond
Watch roundtable 2: Accelerating Cell Therapy Clinical Trials With Comprehensive Biomarker-Driven Strategies
Watch roundtable 3: Companion Diagnostic Approaches in the Development of Cell and Gene Therapies
Watch roundtable 2: Accelerating Cell Therapy Clinical Trials With Comprehensive Biomarker-Driven Strategies
Watch roundtable 3: Companion Diagnostic Approaches in the Development of Cell and Gene Therapies